First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Takeda Pharmaceutical Company Limited

    TAK · 2 developments mapped · last assessed 2026-09-29

    Market Ontology has mapped 2 macro, policy, and market developments to Takeda Pharmaceutical Company Limited since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for TAK yet, so no modelled value is shown. The TAK valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run TAK on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for TAK. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide

      Potential future competition in the hypoparathyroidism market, particularly given their past involvement.

      · Moves market share for existing hypoparathyroidism treatments, pricing power for existing therapies

    What changed, by assumption

    Market share for existing hypoparathyroidism treatments
    • 2026-08-27MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide
    R&d pipeline progress
    • 2026-09-29Keros Therapeutics to Distribute 25% of $20 Million Takeda Milestone to Stockholders

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-29Keros Therapeutics to Distribute 25% of $20 Million Takeda Milestone to Stockholderswatch3-12m0.10
    2026-08-27MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatidewatch1-5y0.40